SK Biopharmaceuticals Co., Ltd. - Product Pipeline Review - 2014

Published: Mar, 2014 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

SK Biopharmaceuticals Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'SK Biopharmaceuticals Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the SK Biopharmaceuticals Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of SK Biopharmaceuticals Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of SK Biopharmaceuticals Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of SK Biopharmaceuticals Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the SK Biopharmaceuticals Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate SK Biopharmaceuticals Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of SK Biopharmaceuticals Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the SK Biopharmaceuticals Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of SK Biopharmaceuticals Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of SK Biopharmaceuticals Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of SK Biopharmaceuticals Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
SK Biopharmaceuticals Co., Ltd. Snapshot 6
SK Biopharmaceuticals Co., Ltd. Overview 6
Key Information 6
Key Facts 6
SK Biopharmaceuticals Co., Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
SK Biopharmaceuticals Co., Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
SK Biopharmaceuticals Co., Ltd. - Pipeline Products Glance 12
SK Biopharmaceuticals Co., Ltd. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
SK Biopharmaceuticals Co., Ltd. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
SK Biopharmaceuticals Co., Ltd. - Early Stage Pipeline Products 15
IND/CTA Filed Products/Combination Treatment Modalities 15
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
SK Biopharmaceuticals Co., Ltd. - Drug Profiles 18
carisbamate 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
SKL-N05 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
SKL-NP 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
YKP-3089 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
YKP-GI 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
SKL-DEP 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SKL-PD 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
YKP-1447 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SKL-15508 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
N-2 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
SKL-16036 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SKL-G 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SKL-PSY 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule for Depression and Schizophrenia 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule for Diabetes 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule for Multiple Sclerosis 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule for Neuropathic Pain 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule for Tauopathies and Alzheimers Disease 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SK Biopharmaceuticals Co., Ltd. - Pipeline Analysis 40
SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Target 40
SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Route of Administration 42
SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Molecule Type 43
SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Mechanism of Action 44
SK Biopharmaceuticals Co., Ltd. - Recent Pipeline Updates 46
SK Biopharmaceuticals Co., Ltd. - Dormant Projects 49
SK Biopharmaceuticals Co., Ltd. - Discontinued Pipeline Products 50
Discontinued Pipeline Product Profiles 50
carisbamate 50
SK Biopharmaceuticals Co., Ltd. - Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables
SK Biopharmaceuticals Co., Ltd., Key Information 6
SK Biopharmaceuticals Co., Ltd., Key Facts 6
SK Biopharmaceuticals Co., Ltd. - Pipeline by Indication, 2014 8
SK Biopharmaceuticals Co., Ltd. - Pipeline by Stage of Development, 2014 10
SK Biopharmaceuticals Co., Ltd. - Monotherapy Products in Pipeline, 2014 11
SK Biopharmaceuticals Co., Ltd. - Phase III, 2014 12
SK Biopharmaceuticals Co., Ltd. - Phase II, 2014 13
SK Biopharmaceuticals Co., Ltd. - Phase I, 2014 14
SK Biopharmaceuticals Co., Ltd. - IND/CTA Filed, 2014 15
SK Biopharmaceuticals Co., Ltd. - Preclinical, 2014 16
SK Biopharmaceuticals Co., Ltd. - Discovery, 2014 17
SK Biopharmaceuticals Co., Ltd. - Pipeline by Target, 2014 41
SK Biopharmaceuticals Co., Ltd. - Pipeline by Route of Administration, 2014 42
SK Biopharmaceuticals Co., Ltd. - Pipeline by Molecule Type, 2014 43
SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 45
SK Biopharmaceuticals Co., Ltd. - Recent Pipeline Updates, 2014 46
SK Biopharmaceuticals Co., Ltd. - Dormant Developmental Projects,2014 49
SK Biopharmaceuticals Co., Ltd. - Discontinued Pipeline Products, 2014 50
SK Biopharmaceuticals Co., Ltd., Other Locations 51
SK Biopharmaceuticals Co., Ltd., Subsidiaries 51